#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

FiveYears Retrospective Study of Latanoprost Glaucoma Treatment


Authors: M. Závorková;  P. Sušický
Authors‘ workplace: Oční oddělení Masarykovy nemocnice, Ústí nad Labem přednosta MUDr. Ivana Liehneová
Published in: Čes. a slov. Oftal., 63, 2007, No. 4, p. 292-298

Overview

Aim:
The authors evaluated their five years experience with 0.005% latanoprost (Xalatan®) glaucoma treatment. They monitored the latanoprost efficiency to lower the intraocular pressure (IOP) and its capability to maintain the target IOP in the long term.

Patients and method:
The group consisted of 118 patients (231 eyes) who are treated for glaucoma with latanoprost. The follow up period was at least 3 years. The patients were checked each three months and the results of the IOP measurement for the study purpose were included once a year.

Results:
The IOP before the latanoprost treatment was 23.4 ± 5.3 mm Hg. The IOP after 1-year latanoprost treatment was 17.6 ± 3.2 mm Hg, after 2 years 17.7 ± 3.9 mm Hg, after 3 years 17.1 ± 3.1 mm Hg, after 4 years 17.1 ± 3.2 mm Hg, and after 5 years 17.6 ± 3.8 mm Hg. The average IOP during the latanoprost treatment was 17.4 ± 3.4 mm Hg, the average lowering of the IOP after the start of the latanoprost treatment was by 6.0 mm Hg. The IOP lowering by 30 % against the IOP value at the time of glaucoma diagnose was reached after 3 years in 82 % (189 out of 231) eyes, after 5 years in 83 % (54 out of 65) eyes.

Conclusion:
Our five years experience confirmed, that latanoptost is a drug significantly lowering and in the long term maintaining the IOP level. As a great advantage, we appreciate the simple application and good compliance.

Key words:
latanoprost, intraocular pressure, uveo-scleral outflow, glaucoma


Labels
Ophthalmology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#